Skip to main content
. 2021 Aug 17;10(8):e1327. doi: 10.1002/cti2.1327

Figure 1.

Figure 1

Anti‐type I IFN antibodies (Abs) in patients with life‐threatening COVID‐19. (a) Auto‐Abs concentrations with neutralizing capacity against IFN‐α. Concentration of auto‐Abs against IFN‐α2 (ng mL−1) was determined by a Thermo Fisher Kit (Catalog # BMS217) in serum samples collected from COVID‐19 patients admitted in ICU (n = 84) and COVID‐19 patients with mild respiratory symptoms (n = 10). (b, c) IFN‐α2 concentration (fg mL−1) (b) and ISG score (c) in plasma and whole blood collected from COVID‐19 patients in the first 15 days after symptom onset [critically ill COVID‐19 patients (n = 54) and mildly symptomatic COVID‐19 patients (n = 10)]. (d) Longitudinal detection of auto‐Abs against IFN‐α2 in COVID‐19 patients' serum during their ICU stay according to the delay post‐symptom. Dotted lines represent positive cut‐off value (threshold), lower limit of quantification (LLOQ) and upper limit of quantification (ULOQ). Solid black lines represent median. Comparisons were performed using the Kruskal–Wallis test followed by Dunn's test. ***P‐value ≤ 0.001 and ****P‐value ≤ 0.0001.